title: Lower-face and neck antiaging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus--part 2.
abstract: BACKGROUND
  Onabotulinumtoxin A has been used for many years in the aging face treatment. A survey was organized to identify current practices in France.
  
  
  OBJECTIVE
  To develop consensual recommendations for treating aging lower face and neck with onabotulinumtoxin A.
  
  
  METHODS
  Fifty-seven participants to six regional surveys reviewed practices and techniques for each individual treatment indication. From conference summaries and data from a questionnaire, consensual recommendations were developed.
  
  
  RESULTS
  General considerations, key treatment rules, injection specifics (dose, site, and techniques), associated procedures/treatments, and procedure follow-up were defined by indication, i.e., nasolabial angle, nasal tip repositioning, dilated nostrils, lips and perioral area, Marionette lines and depressor anguli oris, gingival smile, risorius and zygomatic perioral muscles, masseters, chin, and platysma. For the consensus participants, current onabotulinumtoxin A use is a global preventive and corrective treatment. Overall, judicious treatment of multiple sites and adjunctive modalities, such as fillers, peels, and laser, leads to satisfactory results with a youthful, harmonious, animated, and natural-looking face.
  
  
  CONCLUSIONS
  Years of experience using onabotulinumtoxin A result in sophisticated treatment approaches, more specific targeted injections, and better understanding of lower facial and neck aging, leading to satisfying therapeutic results for patients and clinicians.
authors.affiliation: Facial Plastic Surgery Centre, Palais Armenonville, Rond Point Duboys d'Angers, Cannes, France. doctor@raspaldo.fr
authors.forename: Herve
authors.initials: H
authors.lastname: Raspaldo
authors.forename: Francois-Rene
authors.initials: FR
authors.lastname: Niforos
authors.forename: Veronique
authors.initials: V
authors.lastname: Gassia
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Dallara
authors.forename: Philippe
authors.initials: P
authors.lastname: Bellity
authors.forename: Martine
authors.initials: M
authors.lastname: Baspeyras
authors.forename: Lakhdar
authors.initials: L
authors.lastname: Belhaouari
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002680:Chin; D003625:Data Collection; D005602:France; D006801:Humans; D008046:Lip; D009333:Neck; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D009666:Nose; D012060:Rejuvenation; D015595:Skin Aging / Q000187:drug effects*
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A